pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,751 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints919BioPharma Dive354BioSpace335Fierce Biotech315onclive165raps111globenewswire health
therapy area
allOncology8157Rare Disease1937Cardiology1879Immunology1557Hematology1354Pulmonology1264Vaccines
  • City Therapeutics raises $99.5 million to advance three RNAi drug candidates
    City Therapeutics, a next‑generation RNA interference startup founded by former Alnylam executives, announced it has secured $99.5 million in financing. The capital will be used to move its first…
    Endpoints · 3mo agoDealPositive↗ source
  • GoHealth files for Chapter 11 bankruptcy as Medicare Advantage insurers retreat
    GoHealth, a health‑insurance marketplace that serves seniors, voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court. The filing follows a period of volatility in the Medicare Ad…
    Endpoints · 3mo agoNegative↗ source
← prev
page 59 of 71
next →
73
fda recalls71
fda medwatch62
fda press38
1262
Psychiatry & CNS889
Ophthalmology521
Pain501
Endocrinology & Metabolism495
Infectious Disease457
  • GSK partners with Engitix on multi-target liver research
    GSK announced a collaboration with London-based Engitix to explore multiple targets for liver disease. Engitix will apply its extracellular matrix-based disease models to uncover new therapeutic op…
    Endpoints · 3mo agoDealNeutral↗ source
  • Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidates
    Cavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round. The capital is intended to move its first t…
    Endpoints · 3mo agoDealPositive↗ source
  • Takeda braces for $2.5 billion charge after losing Amitiza antitrust case, plans appeal
    Takeda Pharmaceutical has revised its financial outlook to include a potential $2.5 billion charge stemming from a recent antitrust lawsuit loss involving its laxative product Amitiza. The US Dist…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Novo Nordisk aims to bring triple-G obesity injection to market by 2030
    Novo Nordisk said it plans to launch a triple‑G obesity injection by 2030. The drug would combine agonist activity at the GLP‑1, GIP and glucagon receptors, a class that researchers believe could b…
    Endpoints · 3mo agoPositive↗ source
  • Endpoints News identifies 25 biopharma CEOs earning $25M or more in 2025
    Endpoints News released a ranking of the highest-paid chief executives in the biopharma sector for 2025. For the first time in four years the publication raised the minimum compensation threshold…
    Endpoints · 3mo agoNeutral↗ source
  • Biopharma pay series to return with new installments
    The publisher announced that new installments of its biopharma pay series will be released in the near future. The series traditionally examines compensation trends and salary data across the phar…
    Endpoints · 3mo agoNeutral↗ source
  • Nearly one in five patients stopped Boehringer's obesity shot in Phase 3 trial because of side effects
    Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, was evaluated in the Phase 3 SYNCHRONIZE-1 study. The trial reported that 19% of participants discontinued the treatm…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Pfizer's Berobenatide GLP-1 injection shows efficacy in obesity and diabetes in early data
    Pfizer presented early data on its long-acting GLP-1 injection, Berobenatide, at a conference on June 6, 2026. The results indicated the drug was effective in patients who have both obesity and d…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Roche to launch Phase 2 trial of petrelintide and enicepatide combination for obesity
    Roche announced it will begin a Phase 2 study this year testing a combination of its two obesity candidates, petrelintide and enicepatide. The company describes petrelintide as having a potentiall…
    Endpoints · 3mo agoCRLPositive↗ source
  • Lawmakers propose China restrictions and ASCO 2026 highlights
    The latest Endpoints Weekly notes that U.S. lawmakers are introducing new measures aimed at limiting certain activities with China, though details were not disclosed in the brief. The issue also r…
    Endpoints · 3mo agoNeutral↗ source
  • Roche's daily incretin injection shows promise in Phase 2 trial for type 1 diabetes
    Roche reported that its experimental daily incretin injection achieved positive results in a Phase 2 study involving patients with type 1 diabetes. The study, the first mid-stage trial of a GLP-1…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Innovent Biologics reports Phase 3 success for stomach cancer ADC, now under priority review in China
    Innovent Biologics announced that its antibody‑drug conjugate (ADC) candidate has met the primary endpoint in a Phase 3 trial for advanced stomach cancer. The positive outcome has placed the produ…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Fulcrum Therapeutics cuts workforce, retaining only nine employees as layoffs hit 48 staff
    Fulcrum Therapeutics announced a dramatic reduction in its staff, letting go of 48 of its 57 full‑time employees. The move leaves the company with just nine remaining workers, effectively turning i…
    Endpoints · 3mo agoLayoffsNegative↗ source
  • Biotech lobby groups in Washington push to keep Chinese low-cost drug pipeline open amid rising anti-China proposals
    Washington biotech lobby groups are working to ensure a steady flow of affordable medicines that originate from Chinese manufacturers. These groups have become aware that they are encountering voc…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Industry and rare disease groups call for more transparency in FDA voucher pilot
    The pharmaceutical industry and rare‑disease advocacy groups have voiced concerns about the Commissioner's National Priority Voucher pilot program. Stakeholders say the program lacks transparency…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • House Appropriations Committee urges FDA to accelerate IND approvals for clinical trials
    The House Appropriations Committee issued a directive to the Food and Drug Administration, calling for reforms to speed up the Investigational New Drug (IND) sign-off process for new clinical trial…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Uli Stilz joins Flagship while Revolution Medicines adds Alex Hoffman as commercial lead
    On June 5, 2026, biotech veteran Uli Stilz announced his new position at Flagship, marking a notable personnel shift in the industry. Stilz has spent much of the year traveling internationally, in…
    Endpoints · 3mo agoNeutral↗ source
  • Novo Nordisk Indiana plant faces FDA re-inspection after hair found in drugs and roof leaks threaten sterility
    Novo Nordisk's fill‑finish facility in Bloomington, Indiana underwent a follow‑up FDA inspection in April. The agency reported mammalian hair in finished drug containers and identified water leaks…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Otsuka presents new data to bolster full approval bid for Voyxact in IgA nephropathy
    Otsuka Pharmaceutical announced that new clinical evidence has been generated for its monoclonal antibody Voyxact, aimed at treating IgA nephropathy, a chronic autoimmune kidney disease. The data,…
    Endpoints · 3mo agoRegulatoryPositive↗ source
  • Dimension Capital targets up to $750M for third life-sciences fund after strong portfolio performance
    Dimension Capital, a New York and San Francisco-based investment firm that blends machine learning with life-science ventures, announced it is launching its third fund. The firm is seeking up to $…
    Endpoints · 3mo agoDealPositive↗ source
  • FDA reinspects Novo Nordisk's Indiana plant, finds mammalian hair and roof leaks compromising drug sterility
    Novo Nordisk's manufacturing facility in Indiana, acquired from Catalent, has undergone a second FDA reinspection after earlier concerns. The April inspection revealed mammalian hair in finished d…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Hikma invests $267 million in Ohio as Cingulate receives CRL for ADHD candidate
    Hikma Pharmaceuticals, a generic drugmaker, announced a $267 million investment to expand its manufacturing footprint in Ohio. The plan includes $216 million to upgrade its existing Columbus plant…
    Endpoints · 3mo agoDealNeutral↗ source
  • Novo Holdings invests €500 million in Europe-focused fund as Alnylam advances second obesity drug to clinic
    Novo Holdings, the investment arm of the Novo Nordisk Foundation, has committed €500 million to the Scaleup Europe Fund, a vehicle aimed at supporting European biotech scale‑ups. Alnylam Pharmaceu…
    Endpoints · 3mo agoDealPositive↗ source